Skip to content

Two new formulations receive European go-ahead

Is less than 95% adherence to NNRTIs good enough to lead to viral suppression?

Tipranavir superior to other PIs in detailed resistance analysis

Entecavir gains ground as anti-HBV option in HIV-coinfected patients

TMC114 appears to be strong PI option for salvage therapy

Myocardial infarction risk rises with each year of antiretroviral therapy, but remains low

Investigational NNRTI TMC278 swiftly cuts viral load in treatment-naive patients

Therapeutic vaccine plus interleukin-2 shows best viral control in treatment breaks

Vanguard treatment programmes pave the way to scale up